$BNTC
Benitec Biopharma Inc.

2024 Q1 Form 10-Q Financial Statement

#000119312524032940 Filed on February 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue -$3.000K $1.000K
YoY Change
Gross Profit $3.000K -$1.000K
YoY Change
Gross Profit Margin
Selling, General & Admin $1.578M $1.824M
YoY Change 28.5% -2.09%
% of Gross Profit 52600.0%
Research & Development $2.566M $5.102M
YoY Change -18.98% 35.66%
% of Gross Profit 85533.33%
Depreciation & Amortization $25.00K $17.00K
YoY Change -21.88% -58.54%
% of Gross Profit 833.33%
Operating Expenses $4.141M $6.927M
YoY Change -5.78% 23.17%
Operating Profit -$4.141M -$6.927M
YoY Change -4.61% 23.48%
Interest Expense -$4.000K -$6.000K
YoY Change -42.86% -33.33%
% of Operating Profit
Other Income/Expense, Net -$138.0K $129.0K
YoY Change 146.43% -35.18%
Pretax Income -$4.279M -$6.798M
YoY Change -2.68% 25.63%
Income Tax
% Of Pretax Income
Net Earnings -$4.279M -$6.798M
YoY Change -2.68% 25.63%
Net Earnings / Revenue
Basic Earnings Per Share -$1.64 -$2.64
Diluted Earnings Per Share -$1.64 -$2.64
COMMON SHARES
Basic Shares Outstanding 2.592M 2.572M
Diluted Shares Outstanding 2.616M 2.576M

Balance Sheet

Concept 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.14M $20.37M
YoY Change 115.89% 93.36%
Cash & Equivalents $14.10M $20.40M
Short-Term Investments
Other Short-Term Assets $157.0K $355.0K
YoY Change -79.72% -0.28%
Inventory
Prepaid Expenses $225.0K $435.0K
Receivables $53.00K $53.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $14.37M $20.80M
YoY Change 94.27% 89.49%
LONG-TERM ASSETS
Property, Plant & Equipment $204.0K $51.00K
YoY Change 92.45% -63.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $69.00K $81.00K
YoY Change -34.29% -30.17%
Total Long-Term Assets $633.0K $557.0K
YoY Change -23.27% -40.11%
TOTAL ASSETS
Total Short-Term Assets $14.37M $20.80M
Total Long-Term Assets $633.0K $557.0K
Total Assets $15.00M $21.35M
YoY Change 82.47% 79.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $815.0K $2.619M
YoY Change 28.35% 393.22%
Accrued Expenses $2.543M $3.053M
YoY Change 2.46% 59.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.437M $5.746M
YoY Change 9.01% 130.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $62.00K $137.0K
YoY Change -82.49% -67.54%
Total Long-Term Liabilities $62.00K $137.0K
YoY Change -82.49% -67.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.437M $5.746M
Total Long-Term Liabilities $62.00K $137.0K
Total Liabilities $3.499M $5.883M
YoY Change -0.23% 102.1%
SHAREHOLDERS EQUITY
Retained Earnings -$184.9M -$180.6M
YoY Change 13.29% 13.73%
Common Stock $197.3M $197.1M
YoY Change 16.86% 16.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.50M $15.47M
YoY Change
Total Liabilities & Shareholders Equity $15.00M $21.35M
YoY Change 82.47% 79.36%

Cashflow Statement

Concept 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$4.279M -$6.798M
YoY Change -2.68% 25.63%
Depreciation, Depletion And Amortization $25.00K $17.00K
YoY Change -21.88% -58.54%
Cash From Operating Activities -$6.168M -$5.365M
YoY Change 53.09% -8.18%
INVESTING ACTIVITIES
Capital Expenditures $179.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$179.0K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 39.00K
YoY Change
NET CHANGE
Cash From Operating Activities -6.168M -5.365M
Cash From Investing Activities -179.0K 0.000
Cash From Financing Activities 0.000 39.00K
Net Change In Cash -6.347M -5.326M
YoY Change 57.53% -8.85%
FREE CASH FLOW
Cash From Operating Activities -$6.168M -$5.365M
Capital Expenditures $179.0K
Free Cash Flow -$6.347M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4620206
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001808898
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39267
dei Entity Registrant Name
EntityRegistrantName
BENITEC BIOPHARMA INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line1
EntityAddressAddressLine1
3940 Trust Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
780-0819
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
dei Trading Symbol
TradingSymbol
BNTC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2592434
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20374000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2477000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
14000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
13000
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
53000
CY2023Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
55000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
355000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1184000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
20796000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
3729000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87000
CY2023Q4 us-gaap Deposit Assets
DepositAssets
25000
CY2023Q2 us-gaap Deposit Assets
DepositAssets
25000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
81000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
97000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
526000
CY2023Q4 us-gaap Assets
Assets
21353000
CY2023Q2 us-gaap Assets
Assets
4464000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4937000
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3231000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
523000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
472000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
286000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5746000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3978000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
137000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
284000
CY2023Q4 us-gaap Liabilities
Liabilities
5883000
CY2023Q2 us-gaap Liabilities
Liabilities
4262000
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2592434
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2592434
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1671485
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1671485
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
197063000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
168921000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180641000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167889000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-952000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-830000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
15470000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
202000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21353000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4464000
CY2023Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2022Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14000
CY2023Q4 us-gaap Revenues
Revenues
0
CY2022Q4 us-gaap Revenues
Revenues
14000
us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
14000
CY2023Q4 bntc Royalties And License Fees
RoyaltiesAndLicenseFees
1000
CY2022Q4 bntc Royalties And License Fees
RoyaltiesAndLicenseFees
0
bntc Royalties And License Fees
RoyaltiesAndLicenseFees
-105000
bntc Royalties And License Fees
RoyaltiesAndLicenseFees
0
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5102000
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3761000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9531000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6421000
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1824000
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1863000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3375000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3783000
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
6927000
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
5624000
us-gaap Operating Expenses
OperatingExpenses
12801000
us-gaap Operating Expenses
OperatingExpenses
10204000
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-6927000
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5610000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12801000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10190000
CY2023Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
152000
CY2022Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
161000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
96000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-346000
CY2023Q4 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6000
CY2022Q4 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-9000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-12000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-18000
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16000
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
50000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-34000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
50000
CY2023Q4 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1000
CY2022Q4 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
129000
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
199000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
49000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-314000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-6798000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-5411000
us-gaap Net Income Loss
NetIncomeLoss
-12752000
us-gaap Net Income Loss
NetIncomeLoss
-10504000
CY2023Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-172000
CY2022Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-160000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-122000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
347000
CY2023Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-172000
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-160000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-122000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
347000
CY2023Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6970000
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5571000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12874000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10157000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-6798000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-5411000
us-gaap Net Income Loss
NetIncomeLoss
-12752000
us-gaap Net Income Loss
NetIncomeLoss
-10504000
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.64
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.64
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.34
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.3
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2576347
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2576347
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1621280
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1621280
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2366706
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2366706
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1129926
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1129926
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2882000
CY2022Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1869000
CY2022Q3 bntc Issuance And Exercise Of Prefunded And Common Warrants Net Of Transaction Costs
IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
16015000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
302000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
507000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5093000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
14613000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-48000
CY2022Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-160000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-5411000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8994000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
202000
CY2023Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2964000
CY2023Q3 bntc Issuance And Exercise Of Prefunded And Common Warrants Net Of Transaction Costs
IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
27919000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
91000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
50000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5954000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
22308000
CY2023Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
39000
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
93000
CY2023Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-172000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-6798000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
15470000
us-gaap Net Income Loss
NetIncomeLoss
-12752000
us-gaap Net Income Loss
NetIncomeLoss
-10504000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
83000
bntc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
126000
bntc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
121000
bntc Unrealized Gain Loss On Investment
UnrealizedGainLossOnInvestment
-1000
bntc Unrealized Gain Loss On Investment
UnrealizedGainLossOnInvestment
0
us-gaap Share Based Compensation
ShareBasedCompensation
184000
us-gaap Share Based Compensation
ShareBasedCompensation
254000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
0
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
50000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-846000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-388000
bntc Increasedecrease In Accounts And Other Payables
IncreasedecreaseInAccountsAndOtherPayables
1707000
bntc Increasedecrease In Accounts And Other Payables
IncreasedecreaseInAccountsAndOtherPayables
-50000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
46000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-5000
bntc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-136000
bntc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-125000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9942000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9888000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
bntc Proceeds From Issuance Of Common Stock Pre Funded Warrants And Common Warrants
ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants
30922000
bntc Proceeds From Issuance Of Common Stock Pre Funded Warrants And Common Warrants
ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrants
17884000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2964000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1869000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27958000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16015000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-118000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
348000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17898000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6475000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2490000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4076000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20388000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10551000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-11-22
CY2023Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On July 26, 2023, the Company effected a 1-for-17 reverse stock split (the “Reverse Stock Split”) of its common stock. In accordance with the Reverse Stock Split, 17 pre-split shares of the Company’s common stock were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, pre-funded warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company’s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock.
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related right-of-use asset, valuation of equity-based instruments issued for other than cash, the valuation allowance on deferred tax assets, and accrued research and development expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">affected. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassifications </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts in the prior period have been reclassified to conform with current period presentation. </div></div>
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
14000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
13000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of Risk </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div></div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33644413
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2456032
us-gaap Net Income Loss
NetIncomeLoss
-12800000
us-gaap Net Income Loss
NetIncomeLoss
-10500000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9900000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20400000
CY2023Q4 us-gaap Due From Banks
DueFromBanks
20374000
CY2023Q2 us-gaap Due From Banks
DueFromBanks
2477000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
14000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
13000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
20388000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2490000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
435000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1280000
CY2023Q4 bntc Market Value Of Listed Shares
MarketValueOfListedShares
1000
CY2023Q2 bntc Market Value Of Listed Shares
MarketValueOfListedShares
1000
CY2023Q4 us-gaap Other Assets
OtherAssets
436000
CY2023Q2 us-gaap Other Assets
OtherAssets
1281000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
81000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
97000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
355000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1184000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1405000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1405000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1354000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1318000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87000
CY2023Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36000
CY2022Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
41000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
83000
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2619000
CY2023Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1140000
CY2023Q4 bntc Accrued Licence Fees Current
AccruedLicenceFeesCurrent
2000
CY2023Q2 bntc Accrued Licence Fees Current
AccruedLicenceFeesCurrent
109000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
71000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75000
CY2023Q4 bntc Accrued Clinical Development Project Costs
AccruedClinicalDevelopmentProjectCosts
-2171000
CY2023Q2 bntc Accrued Clinical Development Project Costs
AccruedClinicalDevelopmentProjectCosts
-1838000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
74000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
69000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4937000
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3231000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
526000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
126000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
559000
us-gaap Operating Lease Payments
OperatingLeasePayments
136000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
423000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
137000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
286000
CY2023Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y5M12D
CY2023Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0467
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
147000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
291000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
438000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
15000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
423000
CY2023Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2022Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.22
CY2023Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.9299
CY2023Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
27900000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
33431440
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2348039
CY2023Q2 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
1.92
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
33476440
CY2023Q3 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
1.98
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
33431440
CY2023Q4 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
1.98
CY2023Q4 bntc Class Of Warrants Or Rights Excercisable
ClassOfWarrantsOrRightsExcercisable
33431440
CY2023Q4 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Excercisable
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable
1.98
CY2023Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
93000
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-48000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
184000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
254000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
500000

Files In Submission

Name View Source Status
0001193125-24-032940-index-headers.html Edgar Link pending
0001193125-24-032940-index.html Edgar Link pending
0001193125-24-032940.txt Edgar Link pending
0001193125-24-032940-xbrl.zip Edgar Link pending
bntc-20231231.xsd Edgar Link pending
d663671d10q.htm Edgar Link pending
d663671dex311.htm Edgar Link pending
d663671dex312.htm Edgar Link pending
d663671dex321.htm Edgar Link pending
d663671dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g663671g0130143610710.jpg Edgar Link pending
g663671g0130143610993.jpg Edgar Link pending
g663671g0130143611277.jpg Edgar Link pending
g663671g0130143611522.jpg Edgar Link pending
g663671g0130143611694.jpg Edgar Link pending
g663671g0130143611870.jpg Edgar Link pending
g663671g0130143612133.jpg Edgar Link pending
g663671g0130143612304.jpg Edgar Link pending
g663671g0130143612492.jpg Edgar Link pending
g663671g0130143612693.jpg Edgar Link pending
bntc-20231231_lab.xml Edgar Link unprocessable
bntc-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
d663671d10q_htm.xml Edgar Link completed
g663671g0130143612882.jpg Edgar Link pending
g663671g0130143613126.jpg Edgar Link pending
g663671g0130143613660.jpg Edgar Link pending
g663671g0130143613850.jpg Edgar Link pending
g663671g0130143614128.jpg Edgar Link pending
g663671g0130143614347.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bntc-20231231_def.xml Edgar Link unprocessable
bntc-20231231_cal.xml Edgar Link unprocessable